Studies on kinetics of [3H]beta-funaltrexamine binding to mu opioid receptor
- PMID: 2154672
Studies on kinetics of [3H]beta-funaltrexamine binding to mu opioid receptor
Abstract
beta-Funaltrexamine (beta-FNA) was shown to be a reversible kappa agonist and an irreversible mu antagonist. [3H]beta-FNA at low concentrations (less than 10 nM) covalently binds to mu but not delta or kappa opioid receptors in brain membranes. The interaction between beta-FNA and mu opioid receptors was thought to involve two steps; a reversible ligand-receptor complex is formed before the formation of an irreversible complex, based on observations in bioassays in vitro. In this study, we investigated whether such a two-step process occurred in binding using bovine striatal membranes and determined the kinetic parameters by examining the time courses of both reversible and irreversible binding of [3H]beta-FNA to mu opioid receptors. Specific binding was defined as the difference between binding in the presence of levorphanol and dextrorphan (1 microM). Reversible binding was determined as the difference between membrane (reversible and irreversible) binding and irreversible binding. At 25 degrees, the rate of formation of irreversible [3H]beta-FNA-receptor complex increased as the concentration increased and reached a plateau at 2 nM; further increase in [3H]beta-FNA concentration did not enhance the rate of formation, indicating that the rate saturation effect exists for irreversible binding of [3H]beta-FNA to mu opioid receptors. At 10 degrees and low concentrations (less than 1 nM) of [3H]beta-FNA, appreciable reversible binding to opioid receptors occurred before any irreversible [3H]beta-FNA-receptor complex could be detected. These observations support the notion that reversible binding occurs before alkylation of the receptor. The binding of [3H]beta-FNA to mu opioid receptors was thus modeled to allow for such a two-step process: (formula; see text) A mathematical analysis method was derived to allow determination of all kinetic parameters (k+1, k-1, k2, and Kd) of such a two-step reaction. Values of k2, k+1, k-1, and Kd were determined at 10 degrees for 0.5, 0.25, and 0.125 nM [3H]beta-FNA and were found to be very similar among these three concentrations. Raising the incubation temperature from 10 degrees to 37 degrees greatly enhanced the values of k+1, k-1, and k2 without affecting Kd. At 37 degrees incubation without 200 mM NaCl significantly decreased the values of k+1, k-1, and k2 without affecting Kd. NaCl increased the irreversible binding, probably by shifting the equilibrium towards a conformation that binds more easily with beta-FNA. Under all conditions examined, the value of k-1 was found to be at least 5-fold greater than k2, indicating that the majority of the reversible complex dissociates and only a small portion proceeds to form irreversible complex. This finding is consistent with published observations that only a portion of beta-FNA binding to mu opioid receptors is irreversible. In conclusion, [3H]beta-FNA binds reversibly to mu opioid receptors before forming covalent bonding...
Similar articles
-
Reversible and irreversible binding of beta-funaltrexamine to mu, delta and kappa opioid receptors in guinea pig brain membranes.J Pharmacol Exp Ther. 1986 Nov;239(2):351-7. J Pharmacol Exp Ther. 1986. PMID: 3021954
-
Covalent labeling of mu opioid binding site by [3H]beta-funaltrexamine.Mol Pharmacol. 1987 Sep;32(3):321-9. Mol Pharmacol. 1987. PMID: 2823089
-
Interaction of beta-funaltrexamine with [3H]cycloFOXY binding in rat brain: further evidence that beta-FNA alkylates the opioid receptor complex.Synapse. 1991 Jun;8(2):86-99. doi: 10.1002/syn.890080203. Synapse. 1991. PMID: 1652797
-
Irreversible ligands as probes for drug receptors.NIDA Res Monogr. 1991;112:256-83. NIDA Res Monogr. 1991. PMID: 1661379 Review.
-
Recent studies on a mu opioid binding protein purified from bovine striatal membranes.NIDA Res Monogr. 1992;119:34-8. NIDA Res Monogr. 1992. PMID: 1331797 Review. No abstract available.
Cited by
-
Constitutive μ-opioid receptor activity leads to long-term endogenous analgesia and dependence.Science. 2013 Sep 20;341(6152):1394-9. doi: 10.1126/science.1239403. Science. 2013. PMID: 24052307 Free PMC article.
-
The opioid antagonist, β-funaltrexamine, inhibits NF-κB signaling and chemokine expression in human astrocytes and in mice.Eur J Pharmacol. 2015 Sep 5;762:193-201. doi: 10.1016/j.ejphar.2015.05.040. Epub 2015 May 22. Eur J Pharmacol. 2015. PMID: 26007645 Free PMC article.
-
Β-funaltrexamine inhibits chemokine (CXCL10) expression in normal human astrocytes.Neurochem Int. 2013 Mar;62(4):478-85. doi: 10.1016/j.neuint.2013.01.013. Epub 2013 Jan 31. Neurochem Int. 2013. PMID: 23376103 Free PMC article.
-
A Novel Multi-Target Mu/Delta Opioid Receptor Agonist, HAGD, Produced Potent Peripheral Antinociception with Limited Side Effects in Mice and Minimal Impact on Human Sperm Motility In Vitro.Molecules. 2023 Jan 3;28(1):427. doi: 10.3390/molecules28010427. Molecules. 2023. PMID: 36615612 Free PMC article.
-
Molecular recognition of opioid receptor ligands.AAPS J. 2006 Mar 10;8(1):E126-37. doi: 10.1208/aapsj080115. AAPS J. 2006. PMID: 16584119 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Research Materials